Navigation Links
Baxter Announces Licensing Agreement for Innocoll's Gentamicin Surgical Implant in the United States
Date:8/25/2008

The antibiotic surgical product may reduce incidence of surgical site

infections and reduce post-operative cost and complications

DEERFIELD, Ill. and ASHBURN, Va., Aug. 25 /PRNewswire-FirstCall/ -- Baxter Healthcare Corporation today announced a licensing agreement with Innocoll Pharmaceuticals Ltd, a division of Innocoll, Inc., granting Baxter exclusive rights to market and distribute the company's gentamicin surgical implant in the United States. The gentamicin surgical implant will be the first and only biodegradable, leave-behind antibiotic surgical sponge used as an adjunct (add-on) therapy for prevention and treatment of surgical site infections (SSIs) in the United States. This agreement is expected to add to Baxter's biosurgical portfolio by giving surgeons an innovative option to help reduce risk of post-operative complications of SSIs during surgery.

The collagen-based implant is saturated with a high concentration of an antibiotic, gentamicin, designed to deliver the antibiotic directly to the target tissue while maintaining low levels of the drug in order to potentially reduce infection during and after surgery. The gentamicin surgical implant is fully biodegradable and can be left in the body after surgery. According to the Centers for Disease Control and Prevention, SSIs remain an ongoing problem for surgeons and are a burden on patients and the healthcare system, affecting more that 500,000 patients a year in the United States.

The product was developed using Innocoll's proprietary, collagen-based drug delivery technology, CollaRx, and is indicated outside of the United States as an adjunct to systemic antibiotic therapy for the treatment of localized, deep tissue infections and the prevention of SSIs in both hard and soft tissues.

The implant is approved in 49 countries spanning Europe, Latin America, the Middle East, Africa and Asia. It is currently in two Phase III clinical trials in the United States to
'/>"/>

SOURCE Baxter Healthcare Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Baxter Declares Quarterly Dividend
2. Baxter Raises Full-Year 2008 Outlook Following Strong Second-Quarter Financial Results
3. Bioniche Pharma Acquires Baxters ENLON(R) and ENLON-PLUS(R)
4. Baxters Board of Directors Declares Quarterly Dividend
5. Baxter Reports Solid First Quarter Financial Results and Raises Full-Year Outlook
6. Baxters V-Link Luer-Activated Device With VitalShield Protective Coating Now Available For Hospitals
7. Baxter Announces FDA Approval of ARTISS Slow-Setting Fibrin Sealant in Treatment of Burn Patients
8. Baxters Board of Directors Approves New Share Repurchase Authorization of $2 Billion
9. Baxter and Its Foundation Contribute Nearly $53 Million in 2007 to Address Critical Needs Locally and Globally
10. Baxter to Proceed With Recall of Remaining Heparin Sodium Vial Products
11. Baxter Declares Quarterly Dividend
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... , June 30, 2015  The Dr. Samadi Prostate Cancer ... now offering a full suite of new genetic testing methods ... biopsy, for diagnosing prostate cancer. Dr. ... genetic tests for assessing the risk and optimizing the diagnosis ... "We,re very excited to now offer these revolutionary genetic tests ...
(Date:6/29/2015)... --  Pharnext SAS today announced that data related to ... Charcot-Marie-Tooth Type 1A (CMT1A), is being presented in four posters ... (PNS) Biennial Meeting at the Quebec Congress Center in ... 2, 2015. At Poster Viewing Session 4, four ... 7p.m. EDT: Poster 23: "A Meta-Analysis Of ...
(Date:6/29/2015)... 29, 2015  MiMedx Group, Inc. (NASDAQ: MDXG ... tissue and patent-protected processes to develop and market advanced ... Spine, Sports Medicine, Ophthalmic and Dental sectors of healthcare, ... Petit, has been awarded the Lifetime Achievement Award in ... The Entrepreneur Of The Year Program, ...
(Date:6/29/2015)...   For the seventh year running, Across Health conducted ... digital maturity called the Multichannel Maturometer . The ... maturing fast enough. While it,s true that technology is ... and customers are increasingly "digital natives", pharma still lags ... ...
Breaking Biology Technology:New Revolutionary Genetic Testing for Prostate Cancer Offered at Dr. Samadi's Prostate Cancer Center 2New Revolutionary Genetic Testing for Prostate Cancer Offered at Dr. Samadi's Prostate Cancer Center 3New Revolutionary Genetic Testing for Prostate Cancer Offered at Dr. Samadi's Prostate Cancer Center 4New Revolutionary Genetic Testing for Prostate Cancer Offered at Dr. Samadi's Prostate Cancer Center 5Pharnext's PXT-3003 Featured in Multiple Presentations at 2015 Peripheral Nerve Society Biennial Meeting 2EY Entrepreneur Of The Year Program Recognizes Pete Petit, The Chairman & CEO of MiMedx 2Results from Digital Maturity Study Show Pharma Lagging 2Results from Digital Maturity Study Show Pharma Lagging 3Results from Digital Maturity Study Show Pharma Lagging 4
... BEACH, Calif., Jan. 4, 2011 Genesis Biopharma, Inc. ... company developing targeted cancer therapies, today announced that it ... to which it entered into definitive agreements with accredited ... the Genesis Biopharma common stock for a purchase price ...
... Va., Jan. 3, 2011 BNA Books , a ... Second Edition of ... that provides an in-depth consideration of the entire body of ... (Logo: http://photos.prnewswire.com/prnh/20090529/DC24463LOGO )   ...
... a clinical-stage regenerative medicine company developing novel therapies ... and Drug Administration (FDA) authorized commencement of a ... safety of its lead product, JVS-100, for the ... Stromal-cell Derived Factor 1 (SDF-1), which has been ...
Cached Biology Technology:Genesis Biopharma Raises $845,000 in Private Financings 2New Second Edition of Biotechnology and the Federal Circuit Examines the Court's Decisions on Chemical, Biotechnology, and Pharmaceutical Patent Law Cases 2New Second Edition of Biotechnology and the Federal Circuit Examines the Court's Decisions on Chemical, Biotechnology, and Pharmaceutical Patent Law Cases 3New Second Edition of Biotechnology and the Federal Circuit Examines the Court's Decisions on Chemical, Biotechnology, and Pharmaceutical Patent Law Cases 4Juventas Therapeutics Initiating Phase II Clinical Trial of JVS-100 for Treatment of Critical Limb Ischemia 2Juventas Therapeutics Initiating Phase II Clinical Trial of JVS-100 for Treatment of Critical Limb Ischemia 3
(Date:6/24/2015)... NEW YORK , June 24, 2015 ... Systems market, over the next six years. It contains ... affect the industry, along with their impact from the ... It also discusses the industry, market, and technology ... expected that the need of concerned authorities to efficiently ...
(Date:6/23/2015)... MINNETONKA, Minn. , June 23, 2015 /PRNewswire/ ... technology company that supports the entire spectrum of ... iMedNet ™ , the company,s ... has been awarded a Silver 2015 Stevie® Award ... the Health Products & Services Website category.  The ...
(Date:6/18/2015)... NEW YORK , June 18, 2015 ... in US$ Million by the following Product Segments, which ... Immunoassay Systems, Chemiluminescence Immunoassay Systems, Radio Immunoassay Systems, and ... for the US, Canada , ... Asia-Pacific , Latin America ...
Breaking Biology News(10 mins):Automatic Identification System Market by Class, by Platform, by Application and by Geography - Global Forecasts & Analysis to 2014 - 2020 2MedNet Solutions' iMedNet eClinical Wins Silver Stevie Award 2Global Immunoassay Systems Market 2Global Immunoassay Systems Market 3Global Immunoassay Systems Market 4Global Immunoassay Systems Market 5Global Immunoassay Systems Market 6Global Immunoassay Systems Market 7Global Immunoassay Systems Market 8Global Immunoassay Systems Market 9Global Immunoassay Systems Market 10Global Immunoassay Systems Market 11Global Immunoassay Systems Market 12Global Immunoassay Systems Market 13Global Immunoassay Systems Market 14Global Immunoassay Systems Market 15Global Immunoassay Systems Market 16Global Immunoassay Systems Market 17Global Immunoassay Systems Market 18Global Immunoassay Systems Market 19Global Immunoassay Systems Market 20Global Immunoassay Systems Market 21Global Immunoassay Systems Market 22Global Immunoassay Systems Market 23Global Immunoassay Systems Market 24Global Immunoassay Systems Market 25Global Immunoassay Systems Market 26Global Immunoassay Systems Market 27Global Immunoassay Systems Market 28Global Immunoassay Systems Market 29
... Bloomberg School of Public Health has received $28 million ... the David and Lucile Packard Foundation and the William ... Advance Family Planning advocacy initiative within the Bloomberg School,s ... Health. Advance Family Planning aims to increase ...
... PHILADELPHIAResearchers at the Kimmel Cancer Center at Jefferson (KCC) ... have developed potentially game-changing diagnostic and prognostic genetic tests ... distinguish clinically-relevant cancers. The team, led ... of the KCC and the Chair of the ...
... functional body: as embryos develop and grow, they must form ... the embryo. The exact mechanism underlying this fundamental characteristic, called ... EMBL Heidelberg is now one step closer to understanding it. ... a mouse embryo is controlled by how the expression of ...
Cached Biology News:Bloomberg School receives $28 million for family planning advocacy 2Game changing diagnostic & prognostic prostate cancer genetic tests revealed by Jefferson 2Game changing diagnostic & prognostic prostate cancer genetic tests revealed by Jefferson 3Sync to grow 2
0.2ml Gradient Block MBSR. Robot compatible block ejection mechanism. Stackable. (96 well block - holds 1 plate 0.2ml x 96 well plate)...
A robust formulation of Taq Polymerase supplied with a 10X colored reaction buffer which allows Direct Gel-Loading...
A formulation of our Biolase DNA Polymerase which contains a Red Loading Dye...
Homo sapiens similar to Cytosolic acyl coenzyme A thioester hydrolase Antigen: Peptide...
Biology Products: